What is LUCD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LUCD?

P/E (TTM) is n/a and 52-week range is $0.50 to $1.63 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LUCD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LUCD?

The company profile lists revenue (TTM) near $6M, net income (TTM) near $-5.44B, EPS (TTM) near $-0.38 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lucid Diagnostics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 190.8M shares outstanding, ISIN US54948X1090 when available from company profile and filing metadata.

Lucid Diagnostics Inc

$LUCD

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$0.64

-1.86%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Employees

Website

www.luciddx.com/

IPO

2021-10-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)